

Special Issue

The Role of Antibodies in Combating Bacterial Infections and Antibiotic Resistance

Message from the Guest Editors

Anti-infective antibodies have re-emerged as promising biologics against antimicrobial resistance and novel pathogens. They offer targeted mechanisms to neutralize pathogens, block virulence factors, and modulate host immunity. Unlike traditional antibiotics, antibodies offer high specificity, reduce off-target effects, and have the potential for long-lasting protection, making them attractive for both prophylactic and therapeutic applications.

Recent advances in antibody engineering, including Fc optimization, bispecific formats, nanobody development, and antibody-drug conjugates, have expanded the scope of anti-infective interventions. Clinical successes against RSV and SARS-CoV-2 highlight translational potential. Ongoing research targets multidrug-resistant bacteria, vaccine-challenging pathogens, and emerging viruses. Despite cost, manufacturing, and regulatory challenges, the field evolves rapidly through innovation.

This Special Issue presents cutting-edge research on anti-infective antibodies, spanning molecular design, clinical development, and future directions, fostering cross-disciplinary dialogue to accelerate sustainable infectious disease solutions.

Guest Editors

Prof. Dr. Mattias Collin

Department of Clinical Sciences, Division of Infection Medicine, Faculty of Medicine, Lund University, SE-22184 Lund, Sweden

Dr. Pontus Nordenfelt

Department of Clinical Sciences, Division of Infection Medicine, Faculty of Medicine, Lund University, SE-22184 Lund, Sweden

Deadline for manuscript submissions

30 November 2026



Antibodies

an Open Access Journal
by MDPI

Impact Factor 2.7

CiteScore 4.5

Indexed in PubMed



mdpi.com/si/264186

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)





Antibodies

an Open Access Journal
by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed



[mdpi.com/journal/
antibodies](http://mdpi.com/journal/antibodies)

About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Institute of Biological Chemistry, Technical University Munich, Emil-Erlenmeyer-Forum 5, 85350 Freising-Weihenstephan, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)

